BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19118011)

  • 1. Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia.
    Senyuk V; Rinaldi CR; Li D; Cattaneo F; Stojanovic A; Pane F; Du X; Mahmud N; Dickstein J; Nucifora G
    Cancer Res; 2009 Jan; 69(1):262-71. PubMed ID: 19118011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
    Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
    Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.
    Gonzalez-Villalva A; Piñon-Zarate G; Falcon-Rodriguez C; Lopez-Valdez N; Bizarro-Nevares P; Rojas-Lemus M; Rendon-Huerta E; Colin-Barenque L; Fortoul TI
    Toxicol Ind Health; 2016 May; 32(5):908-18. PubMed ID: 24442345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
    Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
    Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression of signaling proteins in essential thrombocythemia.
    Hui W; Ye F; Zhang W; Liu C; Cui M; Li W; Xu J; Zhang DY
    Ann Hematol; 2013 Sep; 92(9):1229-38. PubMed ID: 23639951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
    Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
    Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
    Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.
    Hobbs CM; Manning H; Bennett C; Vasquez L; Severin S; Brain L; Mazharian A; Guerrero JA; Li J; Soranzo N; Green AR; Watson SP; Ghevaert C
    Blood; 2013 Nov; 122(23):3787-97. PubMed ID: 24085768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
    Randi ML; Brunati AM; Scapin M; Frasson M; Deana R; Magrin E; Fabris F; Donella-Deana A
    Blood; 2010 Jan; 115(3):667-76. PubMed ID: 19965650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.
    Grozovsky R; Begonja AJ; Liu K; Visner G; Hartwig JH; Falet H; Hoffmeister KM
    Nat Med; 2015 Jan; 21(1):47-54. PubMed ID: 25485912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-way translocation (X;20;16)(p11;q13;q23) in essential thrombocythemia implicates NFATC2 in dysregulation of CSF2 expression and megakaryocyte proliferation.
    Vieira L; Vaz A; Matos P; Ambrósio AP; Nogueira M; Marques B; Pereira AM; Jordan P; da Silva MG
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1093-108. PubMed ID: 22911897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
    Tefferi A; Wassie EA; Guglielmelli P; Gangat N; Belachew AA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Pacilli A; Vannucchi AM; Passamonti F
    Am J Hematol; 2014 Aug; 89(8):E121-4. PubMed ID: 24753125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.